Clinical trials: Mild to Moderate Hypertension
Erectile Dysfunction, Pulmonary Arterial Hypertension
Study of the Pharmacokinetics and Safety of TPN171H Tablets in Subjects With Mild ,Moderate Hepatic Insufficiency and Normal Liver Function
The study aims to investigate and compare the effect of TPN171H on subjects with mild and moderate hepatic impairment compared to healthy subjects.
- Trial name
- NCT05185011
- Testing
- TPN171H
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
Glaucoma, Open-Angle
A Prospective Evaluation of Glaucoma Subjects Treated With Two Second Generation iStents and One iStent Supra
Prospective Evaluation of Open-Angle Glaucoma Subjects treated with two second generation iStents and one iStent Supra
- Trial name
- GCF-041 (NCT03255798)
- Testing
- G2 and G3
- Where
- Germany
- Volunteers
- 7 people
- Sponsor
- Glaukos Corporation
Hypertension
A Study of the Safety and Efficacy of Long-Term Nebivolol Use in Hypertensive Patients
The study was conducted to determine the long-term safety and efficacy of nebivolol in patients with mild to moderate hypertension. This was an extension of the Phase III dose ranging studies NEB 202, 302 and 305.
- Trial name
- NCT00200499
- Testing
- Nebivolol
- Where
- United States
- Volunteers
- 845 people
- Sponsor
- Mylan Bertek Pharmaceuticals
Glaucoma, Cataract
Observational Study to Evaluate Long Term Outcomes for Ocular Hypertension and Glaucoma Patients Treated With the SpyGlass Bimatoprost Implant System / IOL Combination
The goal of this clinical trial is to further observe and learn if the SpyGlass Pharma Bimatoprost Implant System / IOL Combination works to treat cataracts and either ocular hypertension or glaucoma.
- Conditions
- Glaucoma, Cataract, Ocular Hypertension
- Trial name
- NCT07154810
- Where
- Honduras
- Volunteers
- 23 people
- Sponsor
- SpyGlass Pharma, Inc.
Hypertension
A Clinical Trial to Evaluate Efficacy, Tolerability, and Pharmacokinetic-Pharmacodynamic Relationship of Fimasartan/Hydrochlorothiazide
A 2-Week, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy, Tolerability, and Pharmacokinetic-Pharmacodynamic Relationship of Fimasartan in Combination with Hydrochlorothiazide in Patients…
- Trial name
- NCT02222480
- Testing
- Fimasartan, Hydrochlorothiazide
- Where
- South Korea
- Volunteers
- 103 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
Pharmacokinetic and Pharmacodynamic Profiles of Aliskiren in Japanese Patients With Mild to Moderate Essential Hypertension
This study will evaluate the pharmacokinetic profile, the effect of rennin inhibition and the relationship among pharmacokinetics, renin-angiotensin system (RAS) biomarkers, and blood pressure lowering effects of oral doses of…
- Trial name
- NCT00424541
- Testing
- SPP100 (aliskiren)
- Where
- Japan
- Volunteers
- 34 people
- Sponsor
- Novartis
Hypertension
Effects of Adalat LA and Coracten on Drug Levels, Blood Pressure, and Heart Rate in Fed Patients With Hypertension
This study compares the effect of Adalat LA to Coracten on drug levels as well as changes in blood pressure and heart rate in fed hypertensive subjects.
- Trial name
- NCT00672113
- Testing
- Adalat (Nifedipine, BAYA1040), Coracten
- Where
- United Kingdom
- Volunteers
- 43 people
- Sponsor
- Bayer
Hypertension
Study to Evaluate Efficacy of Micardis® (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring
The primary aim of the trial is to compare telmisartan 80 mg to valsartan 160 mg in lowering diastolic blood pressure in patients who missed a dose of their medication, as measured by ABPM (change from baseline in mean DBP over…
- Trial name
- NCT02242318
- Testing
- Telmisartan, Valsartan
- Volunteers
- 440 people
- Sponsor
- Boehringer Ingelheim
Hypertension
A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension
A Randomized, Double-Blind, Multicenter, phase III Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan (BR-A-657·K) 30mg Compared to Placebo in Patients with Mild to Moderate Essential Hypertension
- Trial name
- fimasartan (NCT01672476)
- Testing
- Valsartan, Fimasartan
- Where
- South Korea
- Volunteers
- 293 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
Compare the Effects of Lercanidipine Hydrochloride Tablet (Zanidip®) and Felodipine Sustained-Release Tablet for Hypertension
This study will be compare Felodipine sustained-release tablets, to Lercanidipine hydrochloride tablets (Zanidip®) for the treatment of patients with mild-to-moderate primary hypertension and to investigate the influence on…
- Trial name
- Zanidip (NCT01520285)
- Testing
- Zanidip, Felodipine sustained-release tablet
- Where
- China
- Volunteers
- 281 people
- Sponsor
- Lee's Pharmaceutical Limited
Hypertension
MK0954 Versus Placebo for Treatment of Mild to Moderate Hypertension
The study had a 4 week single blind placebo period followed by 12 weeks of double blind treatment. Patients were randomized to one of four treatment arms to evaluate the antihypertensive efficacy of Losartan.
- Trial name
- NCT00888355
- Testing
- losartan potassium
- Volunteers
- 428 people
- Sponsor
- Merck Sharp & Dohme LLC
Obesity, Hypertension
A Study of Efficacy and Safety of Topiramate in the Treatment of Obese Patients With Mild to Moderate Essential Hypertension
The purpose of this study is to compare the efficacy and safety of daily topiramate (96mg or 192mg) versus placebo in obese patients with mild to moderate high blood pressure.
- Trial name
- NCT00236665
- Testing
- topiramate
- Volunteers
- 531 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hypertension, Essential
Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension
The purpose of this study is to determine the blood pressure lowering responses of various dose combinations of nifedipine GITS and candesartan as compared to treatment with each component on their own (monotherapy) and placebo…
- Trial name
- DISTINCT (NCT01303783)
- Testing
- Candesartan cilexetil (Atacand), 4 mg, Candesartan cilexetil (Atacand), 8 mg, Nifedipine GITS (Adalat, BAYA1040), 20 mg
- Where
- 157 sites in United States, Argentina and 11 more
- Volunteers
- 1,381 people
- Sponsor
- Bayer
Hypertension
A Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive Patients
The purpose of this study is to evaluate the efficacy, safety and tolerability of IBI3016 or placebo, given subcutaneously, every 3 or 6 months, at different dose levels in patients with mild to moderate hypertension
- Trial name
- NCT07352969
- Testing
- IBI3016
- Where
- China
- Volunteers
- 352 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Hypertension
A Study of IBI3016 in Japanese Participants
A phase I clinical study to evaluate the safety ,tolerability, pharmacokinetic and pharmocodynamic characteristics of a single subcutaneous does of IBI3016 in Japanese participants with mild to moderate hypertension.
- Trial name
- NCT07838220
- Testing
- IBI3016 Dose 4, IBI3016 Dose 3, IBI3016 Dose 2
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Hypertension
The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients.
The purpose of this study is to evaluate the effects on blood pressure control, pulse wave velocity, as well as safety and tolerability of felodipine single or combine with other drugs in Chinese Hypertension patients.
- Trial name
- NCT02336607
- Testing
- Felodipine tablet (Plendil) alone, Felodipine tablet (Plendil)+Hydrochlorothiazide, Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK)
- Volunteers
- 529 people
- Sponsor
- AstraZeneca
Hypertension
A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3)
This study is being conducted to evaluate the safety and antihypertensive efficacy of MK-0954A (Losartan 50 mg / Hydrochlorothiazide (HCTZ) 12.5 mg) in participants with mild to moderate essential hypertension.
- Trial name
- NCT01431508
- Testing
- Losartan 50 mg / HCTZ 12.5 mg
- Volunteers
- 15 people
- Sponsor
- Organon and Co
Hypertension
A Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With Hypertension
The purpose of this study was to contrast the efficacy and safety of 3 dose levels of nebivolol vs. placebo, when added to a patient's existing antihypertensive medication(s) for 3 months, in patients with mild to moderate…
- Trial name
- NCT00200434
- Testing
- Nebivolol
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Mylan Bertek Pharmaceuticals
Hypertension, Impaired Glucose Tolerance
Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance
The purpose of this study is to determine the safety and efficacy of AR9281, a novel s-EH enzyme inhibitor, in improving glucose metabolism and blood pressure in patients with impaired glucose tolerance and mild to moderate…
- Trial name
- NCT00847899
- Testing
- AR9281
- Where
- 30 sites in United States
- Volunteers
- 150 people
- Sponsor
- Arete Therapeutics
Hypertension
Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of a Vaccine Against Essential Hypertension
CYT006-AngQb is a vaccine that induces a B-cell mediated immune response characterized by the generation of specific antibodies (IgG and IgM) against Angiotensin II. The vaccine is administered by subcutaneous injection.
- Trial name
- NCT00701649
- Testing
- CYT006-AngQb
- Where
- 6 sites in Germany, Switzerland
- Volunteers
- 60 people
- Sponsor
- Cytos Biotechnology AG